• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

SII to sell AstraZeneca vaccine to private hospitals at Rs 600 per dose

expresspharmaApril 23, 2021

Tag: AstraZeneca , SII , Vaccine

The Serum Institute of India said on Wednesday it would sell the AstraZeneca vaccine to the country’s state governments at Rs 400 ($5.30) per dose and to private hospitals at Rs 600 ($7.95).

“Furthermore, owing to the complexity, and urgency of the situation it is challenging to supply it independently to each corporate entity,” it said in a statement. “We would urge all corporate and private individuals to access the vaccines through the state facilitated machinery and private health systems.”

Previous:Continuous Manufacturing Part 2: Industrial Adoption of Continuous Pharmaceutical Manufacturing

Next:Efforts to ramp up production of COVID-19 vaccines, easy availability underway: Renu Swarup

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

SII to sell AstraZeneca vaccine to private hospitals at Rs 600 per dose | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

H7N9 Inactivated Influenza Vaccine by Hualan Bio

H7N9 Inactivated Influenza Vaccine by Hualan Bio
Influenza Vaccine in Syringe

Influenza Vaccine in Syringe
Inactivated flu vaccine

Inactivated flu vaccine
Influenza Vaccine(Split Virion),Inactivated manufactured by Hualan Bio

Influenza Vaccine(Split Virion),Inactivated manufactured by Hualan Bio
Human Vaccine

Human Vaccine
Influenza Vaccine（Split Virion）,Inactivated，Quadrivalent

Influenza Vaccine（Split Virion）,Inactivated，Quadrivalent
Hualan inactivated flu vaccine

Hualan inactivated flu vaccine
Influenza A (H1N1) Vaccine, (Split, Inactivated)

Influenza A (H1N1) Vaccine, (Split, Inactivated)
Hualan's Trivalent Flu Vaccine

Hualan's Trivalent Flu Vaccine
High quality of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

High quality of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service